Lipella Pharmaceuticals Advances Bladder Cancer Candidate

Clinical stage biotechnology company, Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), will publish an abstract at the 2024 American Society of Clinical Oncology (ASCO) meeting which will take place from May 31 through June 4 in Chicago, Illinois. The abstract, titled “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at

Lipella is advancing LP-50 for the treatment of non-muscle invasive bladder cancer (NMIBC). The compound has demonstrated the potential for increasing efficacy while minimizing systemic toxicity in preclinical studies.

There is a critical unmet need for effective treatment for NMIBC, which makes up 75-80% of newly diagnosed bladder cancers.

Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer. Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC). Our abstract includes preclinical data demonstrating the efficacy of intravesical pembrolizumab in mice, including size-reduction in bladder tumors measured via T2 weighted MRI.”

Lipella has made significant expansions to its pipeline in 2024. The company is advancing three IND-approved assets, two of which have been granted Orphan Disease Designation by the FDA.

About Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit or LinkedIn.


This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article


About the Author

Lipella Pharmaceuticals Advances Bladder Cancer Candidate

Catie Corcoran

Biotech Editor